MX2022003215A - Formacion de imagenes especificas para proteina de activacion de fibroblastos (fap) y terapia contra tipos de cancer y otras enfermedades fibroticas e inflamatorias. - Google Patents
Formacion de imagenes especificas para proteina de activacion de fibroblastos (fap) y terapia contra tipos de cancer y otras enfermedades fibroticas e inflamatorias.Info
- Publication number
- MX2022003215A MX2022003215A MX2022003215A MX2022003215A MX2022003215A MX 2022003215 A MX2022003215 A MX 2022003215A MX 2022003215 A MX2022003215 A MX 2022003215A MX 2022003215 A MX2022003215 A MX 2022003215A MX 2022003215 A MX2022003215 A MX 2022003215A
- Authority
- MX
- Mexico
- Prior art keywords
- fap
- fibrotic
- formation
- activation protein
- inflammatory diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962901792P | 2019-09-17 | 2019-09-17 | |
| PCT/US2020/051328 WO2021055641A1 (en) | 2019-09-17 | 2020-09-17 | Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003215A true MX2022003215A (es) | 2022-04-25 |
Family
ID=74883518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003215A MX2022003215A (es) | 2019-09-17 | 2020-09-17 | Formacion de imagenes especificas para proteina de activacion de fibroblastos (fap) y terapia contra tipos de cancer y otras enfermedades fibroticas e inflamatorias. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220409747A1 (enExample) |
| EP (1) | EP4031184A4 (enExample) |
| JP (2) | JP2022548155A (enExample) |
| KR (1) | KR20220066098A (enExample) |
| CN (1) | CN114901315B (enExample) |
| AU (2) | AU2020348781B2 (enExample) |
| BR (1) | BR112022005013A2 (enExample) |
| CA (1) | CA3150890A1 (enExample) |
| IL (1) | IL291386A (enExample) |
| MX (1) | MX2022003215A (enExample) |
| WO (1) | WO2021055641A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| US20230147962A1 (en) * | 2020-02-12 | 2023-05-11 | Philochem Ag | Fibroblast activation protein ligands for targeted delivery applications |
| EP4132921A4 (en) * | 2020-04-09 | 2024-03-27 | Purdue Research Foundation | Pi3 kinase inhibitors and uses thereof |
| US20230405153A1 (en) * | 2022-06-17 | 2023-12-21 | Purdue Research Foundation | Fibroblast activation protein-targeted magnetic resonance imaging agents, compositions, and methods of use |
| WO2023244828A1 (en) * | 2022-06-17 | 2023-12-21 | Purdue Research Foundation | Fibroblast activation protein-targeted nanoparticle magnetic resonance imaging agents |
| KR20260005224A (ko) * | 2023-03-10 | 2026-01-09 | 퍼듀 리서치 파운데이션 | 이중특이적 어댑터 및 종양의 치료 및 암-관련 섬유모세포의 억제에 있어서 이를 범용 car-t 세포와 함께 사용하는 용도 |
| CN122161839A (zh) * | 2024-08-23 | 2026-06-05 | 苏州博锐创合医药有限公司 | 基于环肽和共价弹头的化合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071787B2 (en) * | 2009-03-13 | 2011-12-06 | National Health Research Institutes | Pyrrolidine compounds |
| CN103788071A (zh) * | 2012-11-01 | 2014-05-14 | 中国人民解放军第二军医大学 | N-(5-(喹啉-6-基)吡啶-3-基)苯磺酰胺衍生物、制备方法及治疗用途 |
| KR20180103166A (ko) * | 2016-01-29 | 2018-09-18 | 교와 핫꼬 기린 가부시키가이샤 | 핵산 복합체 |
| JP7162592B2 (ja) * | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| JP2021500373A (ja) * | 2017-10-23 | 2021-01-07 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤 |
| JP7037667B2 (ja) * | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| PH12020551205A1 (en) * | 2018-02-06 | 2021-04-19 | Univ Heidelberg | Fap inhibitors |
| WO2019154859A1 (en) * | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| DE102018126558A1 (de) * | 2018-10-24 | 2020-04-30 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Markierungsvorläufer mit Quadratsäure-Kopplung |
-
2020
- 2020-09-17 KR KR1020227012076A patent/KR20220066098A/ko active Pending
- 2020-09-17 US US17/761,508 patent/US20220409747A1/en active Pending
- 2020-09-17 AU AU2020348781A patent/AU2020348781B2/en active Active
- 2020-09-17 WO PCT/US2020/051328 patent/WO2021055641A1/en not_active Ceased
- 2020-09-17 MX MX2022003215A patent/MX2022003215A/es unknown
- 2020-09-17 CA CA3150890A patent/CA3150890A1/en active Pending
- 2020-09-17 EP EP20865602.5A patent/EP4031184A4/en active Pending
- 2020-09-17 BR BR112022005013A patent/BR112022005013A2/pt unknown
- 2020-09-17 JP JP2022517166A patent/JP2022548155A/ja active Pending
- 2020-09-17 CN CN202080079485.1A patent/CN114901315B/zh active Active
-
2022
- 2022-03-15 IL IL291386A patent/IL291386A/en unknown
-
2025
- 2025-06-09 JP JP2025095652A patent/JP2025131780A/ja active Pending
-
2026
- 2026-02-10 AU AU2026200943A patent/AU2026200943A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4031184A4 (en) | 2023-12-06 |
| AU2026200943A1 (en) | 2026-02-26 |
| CN114901315B (zh) | 2025-04-29 |
| JP2022548155A (ja) | 2022-11-16 |
| CN114901315A (zh) | 2022-08-12 |
| CA3150890A1 (en) | 2021-03-25 |
| US20220409747A1 (en) | 2022-12-29 |
| KR20220066098A (ko) | 2022-05-23 |
| AU2020348781B2 (en) | 2025-11-27 |
| EP4031184A1 (en) | 2022-07-27 |
| BR112022005013A2 (pt) | 2022-06-21 |
| JP2025131780A (ja) | 2025-09-09 |
| AU2020348781A1 (en) | 2022-04-14 |
| WO2021055641A1 (en) | 2021-03-25 |
| IL291386A (en) | 2022-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022005013A2 (pt) | Imageamento direcionado à proteína de ativação de fibroblasto (fap) e terapia de cânceres e outras doenças inflamatórias e fibróticas | |
| CY1123256T1 (el) | Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων | |
| CY1123586T1 (el) | Υποδορια σκευασματα αντισωματος her2 | |
| PE20220256A1 (es) | Sistemas de casx artificiales | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| EA202090776A1 (ru) | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) | |
| MX2020008184A (es) | Receptores de antigeno quimericos dirigidos a cd70. | |
| EA202091846A1 (ru) | Соединения с активностью, индуцирующей ферроптоз, и способы их применения | |
| EP4303583A3 (en) | Methods of treating disorders using csf1r inhibitors cross-reference to related applications | |
| MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
| DOP2017000177A (es) | Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| MX2020012273A (es) | Proteína de union a nkg2d, cd16 y proteína de activación de fibroblastos. | |
| IL286467A (en) | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| FR3084254B1 (fr) | Derives deuteres du lanifibranor | |
| PY2056649A (es) | Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15ra y su uso | |
| CL2018000811A1 (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
| MX2021003368A (es) | Aplicacion del chiglitazar y de compuestos relacionados con el mismo. | |
| MX2022006289A (es) | Tratamiento de canceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12. | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| CL2020002637A1 (es) | Métodos de tratamiento de cáncer. | |
| CO2019006341A2 (es) | Fragmento fab novedoso de anticuerpo anti-muc1 de humano | |
| BR112017023012A2 (pt) | aparelho e método para terminação de corpo de tubulação flexível | |
| CY1121156T1 (el) | Μεθοδοι αντιμετωπισης ινωσης και καρκινων |